Document Classification

Section Type: RESULTS

Text: The median progression-free survival was 11. 5 months (95 % confidence interval [CI], 8. 9 to 16. 7) with nivolumab plus ipilimumab, as compared with 2. 9 months (95 % CI, 2. 8 to 3. 4) with ipilimumab (hazard ratio for death or disease progression, 0. 42 ; 99. 5 % CI, 0. 31 to 0. 57 ; P < 0. 001), and 6. 9 months (95 % CI, 4. 3 to 9. 5) with nivolumab (hazard ratio for the comparison with ipilimumab, 0. 57 ; 99. 5 % CI, 0. 43 to 0. 76 ; P < 0. 001).